Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Monthly Archives: March 2010

Some notes on this blog

TweetWe started the Biopharmconsortium Blog in July of 2009, so it is relatively new. Since that time, we have posted 21 articles (not including this one), 7 of which were posted in 2010. The blog has gradually been picking up a following, and it recently made a “Top 50 Biotech Blogs” list. Thanks to Medicareer…

“Animal Models for Therapeutic Strategies” published by Cambridge Healthtech Institute

TweetOn March 5, 2010, Cambridge Healthtech Institute (CHI) announced the publication of our new book-length report, Animal Models for Therapeutic Strategies. This new Insight Pharma Report discusses the use of animal models to develop new paradigms for drug discovery and development in important human diseases. The report also discusses strategies for developing more predictive animal…

Plexxikon’s discovery of PLX4032, a selective targeted therapeutic for metastatic melanoma

TweetIn our March 2, 2010 blog post, we focused on a Phase I clinical trial of Plexxikon/Roche’s PLX4032, in which clinical researchers led by Keith T. Flaherty achieved a dramatic breakthrough in treatment of metastatic melanoma. Now we shall discuss the discovery of the drug itself, PLX4032. In 2002, a research consortium based at the…

Bringing targeted therapy of metastatic melanoma into the clinic–the crucial role of translational researchers

TweetDuring the week of February 22, 2010, the New York Times (NYT) ran a three-part series on a Phase I trial in 2008/2009 of a targeted therapy for metastatic melanoma, a disease that is almost always fatal within a year. The trial was led by Keith T. Flaherty, M.D. (then at the University of Pennsylvania…